22 completed, 9 unknown, 2 not yet recruiting, 2 recruiting. 11 Phase 4, 9 Phase 2, 8 Phase 3, 7 Phase 1, 3 Not applicable.
Follow sacubitril: new trials by email Literature Review of sacubitril trials Research Report on sacubitril
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity sacubitril/allisartan, Amlodipine - Hypertension | Phase 4 | Not yet recruiting | Jing Liu | 104 | 2025-11-01 | 2025-11-21 |
| ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO], Empagliflozin10Mg Tab - Heart Failure | Not applicable | Completed | Rehab Werida | 180 | 2025-01-01 | 2026-06-02 |
| QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension QR12000 75mg, QR12000 75mg placebo, QR12000 150mg - Essential Hypertension | Phase 3 | Not yet recruiting | Wuhan Createrna Science and Technology Co., Ltd | 810 | 2024-12-30 | 2024-12-06 |
| Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg) Sacubitril and Valsartan-Test product, Sacubitril and Valsartan-Reference product - Chronic Heart Failure | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 48 | 2024-12-28 | 2025-04-10 |
| Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets Sacubitril and Valsartan-Test product, Sacubitril and Valsartan-Reference product - Healthy Subjects | Phase 1 | Unknown | Bio-innova Co., Ltd | 40 | 2024-05-06 | 2024-02-08 |
| A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions Sacubitril and Valsartan Tablets 49mg/51mg, Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg) - Bioequivalence Study | Phase 1 | Unknown | Viatris Inc. | 48 | 2024-04-01 | 2024-02-22 |
| A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions Sacubitril and Valsartan Tablets 97mg/103mg, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg) - Chronic Heart Failure | Phase 1 | Unknown | Viatris Inc. | 48 | 2024-03-01 | 2024-02-20 |
| A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg, Entresto 50 mg - Healthy Volunteers | Phase 1 | Unknown | Dr. Reddy's Laboratories (Thailand) Limited | 48 | 2024-01-01 | 2024-01-05 |
| " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD - Congenital Heart Disease, Heart Failure | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 160 | 2023-02-06 | 2022-11-02 |
| A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension QR12000 Compound Tablets 75 mg, QR12000 Compound Tablets 75 mg placebo, QR12000 Compound Tablets 150 mg - Essential Hypertension | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 391 | 2022-12-29 | 2026-07-14 |
| Sacubitril/Valsartan Versus Valsartan in Heart Failure Sacubitril / Valsartan Oral Tablet, Valsartan 80 mg - Heart Failure | Phase 4 | Completed | Damanhour University | 80 | 2022-01-01 | 2023-06-27 |
| Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction Sacubitril/Valsartan 49/51mg/Tab, Valsartan 80mg/Tab - Myocardial Infarction, Hypertension | Phase 4 | Unknown | Qingdao Central Hospital | 200 | 2021-10-01 | 2021-09-29 |
| Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study Sacubitril / Valsartan Oral Tablet [Entresto], ACEI/ARB - Sacubitril/Valsartan, Hypertension | Recruiting | Beijing Friendship Hospital | 180 | 2021-09-01 | 2025-02-13 | |
| Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 Sacubitril / Valsartan Oral Tablet [Entresto], Placebo - Covid19 | Phase 1 / Phase 2 | Completed | Duke University | 42 | 2021-08-06 | 2024-07-03 |
| National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/Valsartan Sacubitril / Valsartan Oral Tablet [Entresto] - Complex Congenital Heart Disease | Unknown | University Hospital, Grenoble | 50 | 2021-07-01 | 2023-11-29 | |
| Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF. Sacubitril / Valsartan Oral Tablet [Entresto], Enalapril - Chagas Cardiomyopathy | Phase 3 | Unknown | University of Sao Paulo General Hospital | 200 | 2021-05-06 | 2024-04-04 |
| Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device Sacubitril / Valsartan Oral Tablet [Entresto] - Pulmonary Hypertension | Phase 3 | Completed | Germans Trias i Pujol Hospital | 14 | 2020-10-29 | 2021-09-28 |
| NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test - Diabetes Mellitus, Cardiovascular Diseases | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2020-08-15 | 2026-07-28 |
| Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy LCZ696, Placebo - Cardiomyopathy, Hypertrophic | Phase 2 | Completed | Novartis Pharmaceuticals | 46 | 2020-01-08 | 2025-05-16 |
| Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure Sacubitril / Valsartan Oral Tablet [Entresto], Valsartan 80mg Tablet - Hemodialysis Complication, Heart Failure | Not applicable | Unknown | Guangdong Provincial People's Hospital | 118 | 2020-01-01 | 2020-10-06 |
Showing 20 of 37. Sign in to see all of them.
Heart Failure (14) · Hypertension (7) · Heart Failure, Systolic (3) · Dilatation, Pathologic (2) · Essential Hypertension (2) · Hypertrophy, Left Ventricular (2) · Motor Activity (2) · Obesity (2) · COVID-19 (1) · Cardiomyopathy, Hypertrophic (1) · Cardiovascular Diseases (1) · Chagas Cardiomyopathy (1) · Chagas Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1)
Novartis Pharmaceuticals (13) · Viatris Inc. (2) · Wuhan Createrna Science and Technology Co., Ltd (2) · Advanced Accelerator Applications (1) · Beijing Friendship Hospital (1) · Bio-innova Co., Ltd (1) · Damanhour University (1) · Dr. Reddy's Laboratories (Thailand) Limited (1) · Duke University (1) · Germans Trias i Pujol Hospital (1) · Guangdong Provincial People's Hospital (1) · Humanis Saglık Anonim Sirketi (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Jing Liu (1) · Qingdao Central Hospital (1)
United States (13) · China (7) · Spain (7) · France (6) · Canada (5) · Germany (5) · United Kingdom (5) · Finland (4) · Netherlands (4) · Argentina (3) · Denmark (3) · Greece (3) · Hungary (3) · India (3) · Poland (3)
Ariya Khunvichai, Ph.D (2) · Ahmed El-Sherbeni (1) · Assoc. Prof. Somruedee Chatsiricharoenkul, M.D. (1) · Carlos Guizar-Sanchez, MD (1) · Edgar Garcia-Cruz, MD (1) · G. Michael Felker, MD, MHS (1) · Gian Jimenez-Rodriguez, MD (1) · Jessica R Wilson, MD, MSCI (1) · Jing Liu, MD (1) · Jun Teng, MD (1) · Lamiaa Khedr (1) · Lamiaa Khedr, Ass Prof. (1) · Michel Galinier, MD (1)
PMID 35115085, PMID 11500748, PMID 19410718, PMID 20236700, PMID 20398860, PMID 25176015, PMID 25595796, PMID 2596992, PMID 26280447, PMID 27542885, PMID 28330649, PMID 29141857, PMID 29266804, PMID 29754651, PMID 30298996, PMID 30520545, PMID 31162140, PMID 31475295, PMID 31475296, PMID 31825471, PMID 32800511, PMID 32854838, PMID 32865377, PMID 32919915, PMID 32978755, PMID 33012283, PMID 33016100, PMID 33186500, PMID 33189510, PMID 33189630, PMID 33189632, PMID 33309581, PMID 33447845, PMID 33663237, PMID 33778551, PMID 33832352, PMID 33998243, PMID 34758252, PMID 34797725, PMID 35560696, PMID 36082663, PMID 36103292, PMID 36229089, PMID 36321459, PMID 36456072, PMID 36599549, PMID 37125529, PMID 37212758, PMID 37401523, PMID 37609931
2016 (2), 2017 (1), 2019 (1), 2023 (1), R01HL163852 (1)